Growth rate-corrected (GR) dose-response metric signatures across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 3 of 4: Median, upper quartile, and lower quartile GR metrics per perturbagen. - Dataset (ID:20270)
Download: Excel (XLSX), Comma-separated (CSV)
| Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | GR50 lower quartile | GR50 median | GR50 upper quartile | GRmax lower quartile | GRmax median | GRmax upper quartile | GRinf lower quartile | GRinf median | GRinf upper quartile | Hill Coefficient lower quartile | Hill Coefficient median | Hill Coefficient upper quartile | GR_AOC lower quartile | GR_AOC median | GR_AOC upper quartile | GEC50 lower quartile | GEC50 median | GEC50 upper quartile |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Purvalanol A | CDK1 | CDK | 25.2896 | 54.7310 | 100.0000 | 0.0757 | 0.5333 | 0.7416 | -0.0675 | 0.5068 | 0.7450 | 1.0817 | 2.5000 | 4.2404 | 0.0335 | 0.0774 | 0.1767 | 18.1854 | 35.4887 | 52.3768 | |
| GSK923295 | CENPE | Kinesin | 0.0392 | 0.0651 | 0.2250 | -0.5702 | -0.2653 | -0.0001 | -0.5044 | -0.2084 | 0.0089 | 1.0722 | 2.1595 | 3.4297 | 0.3588 | 0.4764 | 0.6241 | 0.0452 | 0.0615 | 1.0057 | |
| Doxorubicin | TOP2 | TOP | 0.1488 | 0.2099 | 0.7023 | -0.9456 | -0.8552 | -0.5483 | -0.8723 | -0.7083 | -0.3772 | 1.0561 | 1.4782 | 2.5260 | 0.5209 | 0.6697 | 0.8073 | 0.2444 | 0.4713 | 1.2126 | |
| L-779450 | BRAF | MAPK | 12.8318 | 28.9246 | 48.0158 | -0.2622 | 0.2749 | 0.3891 | -1.0000 | -0.6190 | -0.1023 | 1.0435 | 1.8204 | 3.7221 | 0.0544 | 0.0922 | 0.1394 | 20.7244 | 44.1580 | 61.2878 | |
| Oxamflatin | HDAC | HDAC | 0.6664 | 0.9513 | 1.6592 | -0.9525 | -0.8858 | -0.8199 | -1.0000 | -0.9857 | -0.8929 | 1.0334 | 1.2610 | 1.4776 | 0.4375 | 0.5175 | 0.6006 | 1.6681 | 2.6703 | 3.8183 | |
| Vorinostat | HDAC | HDAC | 72.1503 | 100.0000 | 100.0000 | -0.8970 | -0.8099 | -0.5591 | -0.9320 | -0.8403 | -0.5970 | 1.0273 | 1.3201 | 1.6251 | 0.4794 | 0.5820 | 0.7389 | 100.0000 | 100.0000 | 100.0000 | |
| Cisplatin | DNA cross-linker | DNA cross-linker | 4.4823 | 11.6380 | 25.2438 | -0.8850 | -0.6449 | -0.2565 | -0.9047 | -0.5931 | -0.2921 | 1.0217 | 1.3698 | 2.2177 | 0.2715 | 0.3752 | 0.4391 | 8.7984 | 21.1543 | 38.4325 | |
| Bosutinib | Src | nRTK | 1.2187 | 1.7497 | 4.1420 | -0.6727 | -0.4219 | -0.1512 | -0.7662 | -0.4684 | -0.1288 | 0.9612 | 1.6575 | 1.9534 | 0.3079 | 0.3819 | 0.4639 | 1.7722 | 2.5602 | 5.3523 | |
| Ibandronate | FDPS | N/A | 49.3295 | 82.7741 | 100.0000 | -0.5209 | -0.1213 | 0.0387 | -0.7048 | -0.2169 | -0.0113 | 0.9599 | 1.4483 | 1.9155 | 0.2062 | 0.2750 | 0.3199 | 66.6332 | 98.6899 | 100.0000 | |
| Epirubicin | TOP2 | TOP | 0.2120 | 0.3019 | 0.4930 | -0.9915 | -0.9463 | -0.8152 | -0.8492 | -0.7437 | -0.6556 | 0.9325 | 1.4047 | 2.1457 | 0.6134 | 0.7438 | 0.8467 | 0.3985 | 0.6015 | 1.3650 | |
| Sigma A6730 | AKT | AKT | 2.0327 | 6.5660 | 11.2198 | -0.9178 | -0.8320 | -0.6777 | -1.0000 | -1.0000 | -0.9546 | 0.9310 | 1.3794 | 2.0044 | 0.2439 | 0.2875 | 0.4042 | 6.3004 | 13.6236 | 19.0461 | |
| Gefitinib | EGFR | ErbB | 6.6704 | 12.9191 | 28.3915 | -0.2671 | 0.0424 | 0.3018 | -0.8465 | -0.5620 | -0.2259 | 0.9170 | 1.3719 | 2.5436 | 0.0767 | 0.1382 | 0.2408 | 9.0805 | 26.2291 | 41.5832 | |
| 17-AAG | HSP90 | HSP90 | 0.0442 | 0.0876 | 0.1713 | -0.7309 | -0.6010 | -0.3062 | -0.5924 | -0.4000 | -0.2370 | 0.8987 | 1.8748 | 3.3051 | 0.4754 | 0.6987 | 0.8282 | 0.0680 | 0.1218 | 0.3890 | |
| AG1478 | EGFR | ErbB | 8.7673 | 51.6075 | 100.0000 | -0.0710 | 0.2684 | 0.6341 | -0.3109 | -0.0273 | 0.4206 | 0.8939 | 1.7205 | 2.6373 | 0.0902 | 0.1531 | 0.2936 | 3.7212 | 36.6666 | 94.4655 | |
| CPT-11 | TOP1 | TOP | 3.1544 | 10.7270 | 20.8553 | -0.5980 | -0.2192 | 0.1666 | -0.9688 | -0.6234 | -0.1292 | 0.8799 | 1.3528 | 1.8883 | 0.1220 | 0.2195 | 0.2928 | 7.3583 | 23.7091 | 36.8667 | |
| Mebendazole | N/A | N/A | 0.2591 | 0.5241 | 2.5192 | -0.2079 | 0.0053 | 0.2103 | -0.2699 | -0.1133 | 0.2272 | 0.7947 | 1.2360 | 1.9961 | 0.2868 | 0.3432 | 0.4692 | 0.3151 | 0.3915 | 2.6571 | |
| Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 36.5873 | 68.4588 | 100.0000 | -0.7737 | -0.2023 | 0.2203 | -0.7439 | -0.3900 | 0.2345 | 0.6570 | 1.9429 | 3.4993 | 0.1339 | 0.2188 | 0.2978 | 54.8881 | 71.4700 | 100.0000 | |
| GSK1070916 | AURK | AURK | 0.6046 | 3.0981 | 6.6549 | -0.8474 | -0.6391 | -0.3610 | -1.0000 | -1.0000 | -0.9999 | 0.6499 | 0.9902 | 1.5949 | 0.2113 | 0.2924 | 0.4314 | 3.5405 | 8.2453 | 15.6107 | |
| Pevonedistat | NAE1 | NAE1 | 0.1439 | 0.3445 | 1.2615 | -0.3074 | -0.0880 | 0.0407 | -0.4612 | -0.1540 | 0.0480 | 0.6476 | 0.9529 | 1.4328 | 0.3433 | 0.4344 | 0.5442 | 0.1672 | 0.7014 | 1.4696 | |
| (Z)-4-Hydroxytamoxifen | ESR1 | N/A | 38.2142 | 72.1652 | 100.0000 | -0.2149 | 0.3051 | 0.6418 | -0.8145 | -0.0997 | 0.5442 | 0.6236 | 1.8012 | 2.9451 | 0.0928 | 0.1395 | 0.2253 | 17.7725 | 43.7586 | 100.0000 | |
| Oxaliplatin | DNA cross-linker | DNA cross-linker | 3.2681 | 4.9333 | 12.0662 | -0.9391 | -0.8084 | -0.7104 | -1.0000 | -1.0000 | -0.9516 | 0.6228 | 0.7486 | 1.0057 | 0.4005 | 0.5419 | 0.5768 | 14.7918 | 22.6957 | 42.6124 | |
| Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.2491 | 0.7096 | 1.5478 | -0.9565 | -0.8762 | -0.7290 | -1.0000 | -1.0000 | -0.9202 | 0.6212 | 0.8572 | 1.4388 | 0.3615 | 0.4228 | 0.5481 | 1.3258 | 2.5025 | 5.3389 | |
| Omipalisib | PI3K | PI3K | 0.0049 | 0.0154 | 0.0397 | -0.8281 | -0.5752 | -0.4164 | -0.8004 | -0.5070 | -0.2908 | 0.6200 | 0.7592 | 0.9464 | 0.6332 | 0.8101 | 0.9689 | 0.0158 | 0.0370 | 0.0945 | |
| TPCA-1 | IKK | NFKB | 4.9121 | 23.5816 | 100.0000 | 0.0988 | 0.4346 | 0.6277 | -0.1071 | 0.3912 | 0.5674 | 0.5796 | 1.2158 | 2.2892 | 0.0966 | 0.1616 | 0.2244 | 2.5700 | 5.7466 | 43.2238 | |
| ZM-447439 | AURK | AURK | 3.5193 | 19.1991 | 100.0000 | -0.0403 | 0.4141 | 0.5578 | -0.1176 | 0.3301 | 0.5652 | 0.5578 | 1.0337 | 2.9596 | 0.1428 | 0.2012 | 0.3024 | 0.6732 | 2.5837 | 16.4745 |